sub:assertion { d:DB05464v:identifier "DB05464" ; v:namespace "drugbank" ; v:uri "http://bio2rdf.org/drugbank:DB05464" ; v:x-identifiers.org <http://identifiers.org/drugbank/DB05464> ; dv:drugbank-id "DB05464" ; dv:x-cas <http://bio2rdf.org/cas:> ; dct:description """NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin. Immunohistochemical studies on pancreatic tissue also showed that NOX-700 therapy effectively preserved islet structure and increased insulin immunoreactivity. It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects."""@en ; dct:identifier "drugbank:DB05464" ; dct:title "NOX-700"@en ; adv:Drug ; rdfs:label "NOX-700 [drugbank:DB05464]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05464> . }